http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
-
ImmunityBio gets FDA acceptance for ANKTIVA bladder cancer filing
-
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
-
ImmunityBio presents bladder cancer treatment comparison data at AUA
-
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
-
ImmunityBio receives five US patents for cancer drug combination
-
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
-
ImmunityBio signs exclusive US deal for Tokyo BCG strain to address shortage
-
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
-
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Me
-
ImmunityBio launches ANKTIVA cancer treatment in Saudi Arabia
-
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
-
ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year
-
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
-
ImmunityBio responds to FDA concerns over promotional materials
-
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
-
ImmunityBio secures $100 million in financing with debt conversion
-
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy P
-
ImmunityBio bladder cancer trial meets statistical power requirements
-
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission
-
ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer
-
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
-
NCCN updates bladder cancer guidelines to include ImmunityBio's ANKTIVA
-
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
-
ImmunityBio completes NK cell manufacturing programs with 74 subjects
-
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
-
ImmunityBio resubmits cancer treatment application to FDA
-
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
-
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
-
ImmunityBio completes enrollment in bladder cancer trial ahead of schedule
-
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
-
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
-
ImmunityBio starts phase 2 trial for chemotherapy-free lymphoma treatment
-
ImmunityBio begins phase 2 trial of chemotherapy-free lymphoma treatment
-
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
-
ImmunityBio reports survival data from glioblastoma trial
-
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
-
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
-
ImmunityBio reports 15-month response in lymphoma cell therapy trial
-
ImmunityBio reports progress in bladder cancer trial enrollment
-
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
-
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
-
ImmunityBio reports $113 million revenue, 700% annual increase
-
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
-
ImmunityBio gets Saudi approval for bladder cancer treatment ANKTIVA
-
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
-
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
-
ImmunityBio reports positive lung cancer trial results for ANKTIVA
-
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
-
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
